High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy
Leslee Sprague(The Ohio State University), Timothy P. Cripe(Nationwide Children's Hospital)
Cited by 13
Related Papers
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
|Clinical Cancer Research|2017|137
Effective <i>in vivo</i> targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
|Molecular Cancer Therapeutics|2008|128